View Author
patient study group hypertension concentration health plasma count therapy nvp therapy treatment blood population disease baseline pressure blood pressure level analysis insurance switch antiretroviral signi ficantly women prevention signi prevalence virological dose reduction netherland cvd prevention care factor program regimen efavirenz nigeria nevirapine university nvp plasma concentrations atv switch group cart group table atazanavir namibia pregnancy hiv-infected patients virological failure hiv-infected amsterdam effect survey diabetes reduction ficantly household hospital tanzania sample atovaquone lopinavir /ritonavir result status quality failure treatment-experienced patients kenya change risk factors discontinuation community country centre plasma concentrations /ritonavir treatment-naive patients insurance program cholesterol <.0001 respondent response
7 Most Recent Publications
|
Hypertension in Sub-Saharan Africa: Cross-sectional surveys in four rural and urban communities
(Article)
Hendriks, M.E. Wit, F.W. Janssens, W. Lammers, J. Kramer, B. Bonfrer, I.E.J. None Gaeb, E. Gaag, J. van der Rinke de Wit, T.F. Lange, J.M.A. Schultsz, C. Roos, M.T.L. Brewster, L. Akande, T. Beer, I.H. de Mfinanga, S.G. Kahwa, A.M. Gatongi, P. Rooy, G. van |
2012-03-12
|
|
Cardiovascular disease prevention in rural Nigeria in the context of a community based health insurance scheme: QUality improvement cardiovascular care Kwara-I (QUICK-I)
(Article)
Hendriks, M. Brewster, L. Agbede, K. Akande, T. Lange, J. Schultsz, C. Wit, F.W. Bolarinwa, O.A. Odusola, A.O. Orlewska, E. Bindraban, N. Vollaard, A. Alli, S. Adenusi, P. |
2011-03-31
|
|
Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir
(Article)
Luin, M. van Ende, M.E. van der Kuks, P.F. Burger, D.M. Richter, C. Visser, M. Faraj, D. Ven, A. van der Gelinck, L.B.S. Kroon, F.P. Wit, F.W. Schaik, R.H.N. van |
2010-05-01
|
|
Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations
(Article)
Luin, M. van Gras, L. Richter, C. Ende, M.E. van der Prins, J.M. Wolf, F.D. Burger, D.M. Wit, F.W. |
2009-10-01
|
|
Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir
(Article)
Vonderen, M.G.A. van Gras, L. Wit, F.W. Brinkman, K. Ende, M.E. van der Hoepelman, I.M. Wolf, F. de Reiss, P. |
2009-01-01
|
|
Steady-state nevirapine plasma concentrations are influenced by pregnancy
(Article)
Nellen, J.F.J.B. Damming, M. Godfried, M.H. Boer, K. Ende, M.E. van der Burger, D.M. Wolf, F. de Wit, F.W. Prins, J.M. |
2008-04-01
|
|
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: The ATHENA cohort study
(Article)
Wit, F.W. Kesselring, A.M. Gras, L. Richter, C. Ende, M.E. van der Brinkman, K. Lange, J.M.A. Wolf, F. de Reiss, P. |
2008-03-15
|
